Strontium ranelate, a therapeutic for osteoporosis, was thought to have a dual mode of action, simultaneously stimulating bone formation and reducing resorption. A recent study casts doubt on this ...

Sept. 26, 2005 (Nashville) -- Strontium ranelate is one of the first drugs to have a dual action that both decreases bone resorption and increases bone formation, according to a study presented here ...

London, UK - A new drug for the treatment of osteoporosis, strontium ranelate (Protelos, Servier), was launched this week in the UK and has also been launched in Ireland and Germany. Additional ...

In contrast to previous findings, a nested case–control study did not find evidence of an increased risk of cardiac events associated with the use of strontium ranelate in women with postmenopausal ...